Bifogade filer
Kurs
+2,82%
Likviditet
0,09 MSEK
Prenumeration
Kalender
Est. tid* | ||
2026-02-13 | 08:30 | Bokslutskommuniké 2025 |
2025-11-05 | 08:00 | Kvartalsrapport 2025-Q3 |
2025-08-20 | 08:00 | Kvartalsrapport 2025-Q2 |
2025-05-15 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2025-05-14 | - | Årsstämma |
2025-05-14 | - | Kvartalsrapport 2025-Q1 |
2025-02-13 | - | Bokslutskommuniké 2024 |
2024-11-08 | - | Kvartalsrapport 2024-Q3 |
2024-08-22 | - | Kvartalsrapport 2024-Q2 |
2024-05-16 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2024-05-15 | - | Årsstämma |
2024-05-15 | - | Kvartalsrapport 2024-Q1 |
2024-02-14 | - | Bokslutskommuniké 2023 |
2023-08-24 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-02-16 | - | Bokslutskommuniké 2022 |
2022-08-18 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2022-05-05 | - | Årsstämma |
2022-02-11 | - | Bokslutskommuniké 2021 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-06 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2021-05-05 | - | Årsstämma |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-11 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2020-05-08 | - | Årsstämma |
2020-02-13 | - | Bokslutskommuniké 2019 |
2019-12-18 | - | Extra Bolagsstämma 2019 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-16 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2019-05-15 | - | Årsstämma |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-08-22 | - | Kvartalsrapport 2018-Q2 |
2018-05-09 | - | X-dag ordinarie utdelning SENZA 0.00 SEK |
2018-05-08 | - | Årsstämma |
2018-02-14 | - | Bokslutskommuniké 2017 |
Beskrivning
Land | Sverige |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
SenzaGen has today published its 2024 Annual Report. A digital copy can be downloaded at www.senzagen.com or read via the link below.
To request a printed copy, please email name and address to IR@senzagen.com.
Contact
Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31
Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobil: 0708-20 29 44
About us
SenzaGen is a corporate group that aims to be a leader in in vitro science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.
SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company’s Certified Adviser.